236 related articles for article (PubMed ID: 28099487)
41. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
42. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo.
Gu X; Song X; Dong Y; Cai H; Walters E; Zhang R; Pang X; Xie T; Guo Y; Sridhar R; Califano JA
Clin Cancer Res; 2008 Mar; 14(6):1840-8. PubMed ID: 18347187
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
[TBL] [Abstract][Full Text] [Related]
44. A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.
Klinghammer K; Keller J; George J; Hoffmann J; Chan EL; Hayman MJ
Int J Cancer; 2018 Jan; 142(1):156-164. PubMed ID: 28906000
[TBL] [Abstract][Full Text] [Related]
45. Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
Verma A; Rich LJ; Vincent-Chong VK; Seshadri M
J Oral Pathol Med; 2018 May; 47(5):484-491. PubMed ID: 29573032
[TBL] [Abstract][Full Text] [Related]
46. Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
Young NR; Soneru C; Liu J; Grushko TA; Hardeman A; Olopade OI; Baum A; Solca F; Cohen EE
Target Oncol; 2015 Dec; 10(4):501-8. PubMed ID: 25559287
[TBL] [Abstract][Full Text] [Related]
47. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
[TBL] [Abstract][Full Text] [Related]
48. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
49. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
50. AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab.
Li X; Lu Y; Lu H; Luo J; Hong Y; Fan Z
Oncotarget; 2015 May; 6(13):11507-18. PubMed ID: 25871473
[TBL] [Abstract][Full Text] [Related]
51. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
52. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
[TBL] [Abstract][Full Text] [Related]
53. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
54. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
[TBL] [Abstract][Full Text] [Related]
55. Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.
Putker M; Millen R; Overmeer R; Driehuis E; Zandvliet MMJM; Clevers H; Boj SF; Li QX
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33999032
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short-term culture of tumor slices.
Peria M; Donnadieu J; Racz C; Ikoli JF; Galmiche A; Chauffert B; Page C
Head Neck; 2016 Apr; 38 Suppl 1():E911-5. PubMed ID: 25994489
[TBL] [Abstract][Full Text] [Related]
57. Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures.
Boehnke K; Iversen PW; Schumacher D; Lallena MJ; Haro R; Amat J; Haybaeck J; Liebs S; Lange M; Schäfer R; Regenbrecht CR; Reinhard C; Velasco JA
J Biomol Screen; 2016 Oct; 21(9):931-41. PubMed ID: 27233291
[TBL] [Abstract][Full Text] [Related]
58. The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.
Yang Y; Yan J; Huang Y; Xu H; Zhang Y; Hu R; Jiang J; Chen Z; Jiang H
Biomed Pharmacother; 2015 Mar; 70():181-9. PubMed ID: 25776499
[TBL] [Abstract][Full Text] [Related]
59. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
[TBL] [Abstract][Full Text] [Related]
60. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Chamorey E; Yahia HB; Marcie S; Gautier M; Penault-Llorca F; Milano G
Head Neck; 2017 Jan; 39(1):151-159. PubMed ID: 27507562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
